DK1427708T3 - Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme - Google Patents

Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme

Info

Publication number
DK1427708T3
DK1427708T3 DK02758416T DK02758416T DK1427708T3 DK 1427708 T3 DK1427708 T3 DK 1427708T3 DK 02758416 T DK02758416 T DK 02758416T DK 02758416 T DK02758416 T DK 02758416T DK 1427708 T3 DK1427708 T3 DK 1427708T3
Authority
DK
Denmark
Prior art keywords
amino
pharmaceutical compositions
processes
preparation
same
Prior art date
Application number
DK02758416T
Other languages
Danish (da)
English (en)
Inventor
Maurizio Pulici
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of DK1427708T3 publication Critical patent/DK1427708T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
DK02758416T 2001-08-07 2002-07-30 Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme DK1427708T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/922,729 US20030073692A1 (en) 2001-08-07 2001-08-07 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
PCT/EP2002/008544 WO2003014090A1 (fr) 2001-08-07 2002-07-30 Derives d'amino-phtalazinone actifs comme inhibiteurs de kinase, processus de preparation et compositions pharmaceutiques contenant ces derives

Publications (1)

Publication Number Publication Date
DK1427708T3 true DK1427708T3 (da) 2008-11-24

Family

ID=25447517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02758416T DK1427708T3 (da) 2001-08-07 2002-07-30 Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme

Country Status (23)

Country Link
US (2) US20030073692A1 (fr)
EP (1) EP1427708B1 (fr)
JP (1) JP2005501085A (fr)
KR (1) KR20040029400A (fr)
CN (2) CN101085759A (fr)
AT (1) ATE407928T1 (fr)
BR (1) BR0211807A (fr)
CA (1) CA2455759A1 (fr)
CO (1) CO5560573A2 (fr)
CZ (1) CZ2004305A3 (fr)
DE (1) DE60228857D1 (fr)
DK (1) DK1427708T3 (fr)
EA (1) EA006645B1 (fr)
ES (1) ES2315385T3 (fr)
IL (1) IL159843A0 (fr)
MX (1) MXPA04000905A (fr)
NO (1) NO20040547L (fr)
NZ (1) NZ531310A (fr)
PL (1) PL368440A1 (fr)
PT (1) PT1427708E (fr)
SI (1) SI1427708T1 (fr)
WO (1) WO2003014090A1 (fr)
ZA (1) ZA200401316B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
DE602004031037D1 (de) * 2003-11-19 2011-02-24 Array Biopharma Inc Heterocyclische inhibitoren von mek
DK2305221T3 (en) 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
WO2005061519A1 (fr) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Inhibiteurs de kinase
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
EP1778669A2 (fr) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Inhibiteurs de kinase
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CA2579240A1 (fr) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Petits modulateurs moleculaires de l'activite de cytokines
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
KR101292598B1 (ko) * 2005-01-14 2013-08-05 질레드 코네티컷 인코포레이티드 키나아제 활성 조절제로서의 １，３-디아릴 치환된 우레아
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR20080095912A (ko) * 2006-03-20 2008-10-29 에프. 호프만-라 로슈 아게 프탈라지논 피라졸 유도체, 그의 제조 및 약학적 제제로서의 용도
EP2041087A1 (fr) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited Dérivés d'oxybenzamide 2 en tant qu'inhibiteurs d'activité parp
WO2007144652A2 (fr) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Inhibiteurs de parp
JP2009539962A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008061108A2 (fr) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Dérivés de phtalazine
JP5337717B2 (ja) 2007-02-27 2013-11-06 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なイソキノリノピロロピリジノン
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
EP2003129B1 (fr) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. Dérivés de 1H-pyrido[3,4-B]indol-1-one et de 2,3,4,9-tétrahydro-1H-bêta-carbolin-1-one
EP2215082B1 (fr) * 2007-10-11 2011-09-21 Glaxo Group Limited Phthalazine et composés pyrido[3,4-d]pyridazine comme antagonistes du récepteur h1
KR101598231B1 (ko) * 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
US8772326B2 (en) 2008-07-10 2014-07-08 Anigion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2346495B2 (fr) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Formulation pharmaceutique 514
WO2010042646A1 (fr) 2008-10-10 2010-04-15 Amgen Inc. Composés d'aza- et de diaza-phtalazine en tant que modulateurs de map kinase p38 et procédés pour les utiliser
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US20110098304A1 (en) * 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity
AR079774A1 (es) * 2009-07-15 2012-02-22 Astrazeneca Ab Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo
CN102933571A (zh) * 2010-04-16 2013-02-13 Abbvie公司 激酶的酞嗪-(2h)-酮抑制剂
CN103058927B (zh) * 2011-10-21 2015-04-22 华国媛 一种喹啉衍生物及其应用
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
CN107298640B (zh) * 2017-07-19 2020-08-04 曲阜师范大学 一种亚甲基酮化合物的制备方法及其应用
BR112021020367A2 (pt) 2019-04-11 2021-12-07 Angion Biomedica Corp Formas sólidas de (e)-3-[2-(2-tienil)vinil] -1h-pirazol
US11479551B2 (en) 2019-09-12 2022-10-25 Mirati Therapeutics, Inc. MTA-cooperative PRMT5 inhibitors
WO2023125540A1 (fr) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 Composé pyrazole-1(2h)-phtalazinone et application associée
CN116903611A (zh) * 2022-01-26 2023-10-20 上海优理惠生医药有限公司 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (fr) * 1957-05-07
EP0600831A1 (fr) * 1992-11-27 1994-06-08 Ciba-Geigy Ag Dérivés de phtalazinone
EP0634404A1 (fr) * 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Dérivés de phtalazine et leur utilisation comme pesticides
JPH0961961A (ja) * 1995-08-21 1997-03-07 Fuji Photo Film Co Ltd 熱現像感光材料
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP0875512A3 (fr) 1997-04-16 1999-04-07 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de la naphthylpipérazine avec une activité antipsychotique
BR0009650A (pt) * 1999-04-09 2002-01-02 Meiji Seika Kaisha Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto

Also Published As

Publication number Publication date
BR0211807A (pt) 2004-09-21
KR20040029400A (ko) 2004-04-06
IL159843A0 (en) 2004-06-20
ES2315385T3 (es) 2009-04-01
CO5560573A2 (es) 2005-09-30
ZA200401316B (en) 2005-03-10
EP1427708A1 (fr) 2004-06-16
JP2005501085A (ja) 2005-01-13
NZ531310A (en) 2006-02-24
MXPA04000905A (es) 2004-04-02
EA006645B1 (ru) 2006-02-24
DE60228857D1 (de) 2008-10-23
WO2003014090A1 (fr) 2003-02-20
US7432263B2 (en) 2008-10-07
CN101085759A (zh) 2007-12-12
CA2455759A1 (fr) 2003-02-20
NO20040547L (no) 2004-03-03
EA200400283A1 (ru) 2004-08-26
SI1427708T1 (sl) 2008-12-31
CZ2004305A3 (cs) 2004-08-18
ATE407928T1 (de) 2008-09-15
US20050020583A1 (en) 2005-01-27
PL368440A1 (en) 2005-03-21
PT1427708E (pt) 2008-11-20
CN1538960A (zh) 2004-10-20
US20030073692A1 (en) 2003-04-17
EP1427708B1 (fr) 2008-09-10

Similar Documents

Publication Publication Date Title
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
NO20041086L (no) Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
CA2486101A1 (fr) Derives d'aminoindazole agissant comme inhibiteurs de kinase, methode d'obtention et compositions pharmaceutiques les renfermant
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
GB0330043D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren